mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

(June 19, 2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading


Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient

(June 18, 2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the... Continue Reading


FDA Approves Merck’s Keytruda® for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1

(June 18, 2018)

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.  Keytruda is the... Continue Reading


University of Colorado Study Suggests new Combination Treatment for Head and Neck Cancer

(June 14, 2018)

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments... Continue Reading


Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer

(June 6, 2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading


Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

(June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading


Loxo-292 Promising for Lung and Other “RET Fusion” Cancers

(June 4, 2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About... Continue Reading


FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma

(May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading


Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported

(May 30, 2018)

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain... Continue Reading


Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

(May 29, 2018)

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive... Continue Reading


FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

(May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading


FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who... Continue Reading


« Previous PageNext Page »